| Theme | Gastrointestinal Complications in Dialysis Patients | |
|---|---|---|
| Title | Helicobacter pylori infection -- the prevalence, diagnosis, and eradication therapy in hemodialysis patients | |
| Publish Date | 2002/11 | |
| Author | Hirofumi Nishikage | Department of Internal Medicine Division of Kidney and Dialysis, Hyogo College of Medicine |
| Author | Takeshi Nakanishi | Department of Internal Medicine Division of Kidney and Dialysis, Hyogo College of Medicine |
| Author | Yoshihiro Takamitsu | Department of Internal Medicine Division of Kidney and Dialysis, Hyogo College of Medicine |
| [ Summary ] | It is currently accepted that Helicobacter pylori (H.pylori) infection is crucial in the pathogenesis of peptic ulcers. The prevalence of H.pylori infection in hemodialysis patients is less or almost the same as that seen in the non-renal disease group. In diagnosis, much attention must be paid to the guidelines in the management of H.pylori infection in Japan. Since November 2000, the cost of eradication of H.pylori has been covered by national health insurance in Japan. Triple treatment with proton pump inhibitors (lansoplazole or omeprazole), amoxicillin, and clarithromycin is effective in the general population. Limited data are available on the eradication of H.pylori in hemodialysis patients. The optimum regimen in hemodialysis patients has yet to be established, due to several reasons: lower patient compliance, unknown pharmacokinetics of antibiotics in insufficient renal functioning, and high frequency of side effects. | |